Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to cut opioid use after knee replacement

NCT ID NCT07624526

Symptom relief Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding suzetrigine (Journavx) to standard pain management can lower pain and reduce the need for opioid painkillers after total knee replacement. About 75 adults with knee arthritis will take the drug as part of their post-surgery care. The goal is to improve pain control and limit opioid use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 95 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing primary total knee arthroplasty for osteoarthritis of the knee. * Patients between the ages of 18 and 95 years. Exclusion Criteria: * Patients with concurrent and significant injuries to other bones or organs. * Patients with local infections. * Minors unable to provide informed consent for participation in the study. * Subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures. * Patients with pre-existing immune suppression, where further immune suppression with GCs could warrant unwarranted or unneeded risk. * Patients with preoperative opioid use, defined as daily use less than 4 weeks before the index surgery. * Patients with a history of severe heart disease (NYHA2), renal failure, or liver dysfunction * Patients with active peptic ulcer disease. * Patients neurological or psychiatric diseases, potentially influencing pain perception * Patients who are pregnant. * Patients with a history of alcohol or medical abuse, allergies to glucocorticoids, current daily use of glucocorticoids. * Patients who are unable to take NSAIDs. * Patients who receive Deep Venous Thrombosis (DVT) prophylaxis different than Aspirin (81mg) twice daily (BID). * Patients who have known diabetes mellitus as defined with an A1C greater than 6.5%. * Patients currently taking CYP3A inhibitors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Knee arthritis Knee osteoarthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Emory Clinic

    Atlanta, Georgia, 30322, United States

  • Emory Clinic at Executive Park

    Atlanta, Georgia, 30329, United States

  • Emory Orthopaedics and Spine Center

    Atlanta, Georgia, 30329, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.